MET and neoplasm: While preliminary data from patient subsets in randomized Phase II trials have shown that high MET protein expression as measured by IHC can differentiate patients who may benefit from MET pathway blockade, the success of MET IHC as a predictive biomarker has not been universal in all tumor types [48].